Batm Advanced Communicat... Share Discussion Threads

[markyt] 27/2/2020 16:30

Quite a few b n b ers in for the night see what tomorrow brings

[master rsi] 27/2/2020 16:24

Results next week 4th March

At Interims, the company was back into profits
Adj.* operating profit of $1.6m (H1 2018: $0.6m loss)
· EBITDA of $3.9m (H1 2018: $0.5m)
· Earnings per share of 0.14¢ (H1 2018: 0.35¢ loss per share)

Company Outlook
· Entered H2 2019 with a substantially higher order book
· Networking and Cyber division expected to deliver significantly higher revenue in H2 2019 compared with H1 2019
· Ramp-up in NFV-related revenue
· First NATlab instrument

[master rsi] 27/2/2020 15:56

What from here?

Share price brought down to earlier intraday low and now is moving higher as some medium-size "O" trades are appearing on the ticker

[master rsi] 27/2/2020 15:48

Good for you, pitty that is a small amount --> 338

[fse] 27/2/2020 15:39

Israel’s BATM Advanced, a provider of real-time tech for networking solutions and medical laboratory systems, announced on Thursday that it developed a quick and accurate diagnostics kit for the novel coronavirus, known as 2019-nCoV. The virus causes the disease called COVID-19 which has, as of February 26, claimed the lives of over 2,800 people, mainly in mainland China, and infected over 82,000 worldwide (according to this live-updating map of the outbreak that draws figures from the World Health Organization and other agencies).

BATM Advanced said the kit, developed by its bio-medical division, will allow laboratories to detect whether a patient has the virus in approximately 25 minutes. The kit has undergone testing by several central laboratories and hospitals, and BATM said it will begin production of the kit at the company’s Adaltis facility in Rome.

The company said it is working with academic and research institutions, primarily in Europe, to make the kit affordable for large-scale production. BATM said laboratory bench tests will begin as soon as possible.

BATM’s CEO Dr. Zvi Marom tells NoCamels that the biomed firm received a sequence of the virus, and subsequently the virus itself, for testing purposes. Dr. Marom says the company already has an advanced diagnostics kit that can detect SARS (Severe Acute Respiratory Syndrome) and MERS (Middle East Respiratory Syndrome) “and COVID-19 is a related disease so the idea is to have the kit be able to differentiate between them.”

Dr. Marom says BATM has been in touch with colleagues in China and other countries from the beginning of the outbreak, trying to learn as much as possible about the virus to develop a diagnostic solution.

BATM said the COVID-19 diagnosis system will also be included in a suite of testing kits for travel panels developed by its subsidiary Ador Diagnostics, which is focused on the development of unique in-vitro molecular diagnostics. Ador developed a molecular biology solution called NATLab that provides rapid diagnosis of bacterial, viral or fungal infections within approximately 15-90 minutes, using DNA sampling. NATLab received its first commercial order in January.

[supertag] 27/2/2020 15:09

share price all over the place!

[fse] 27/2/2020 15:05

The IP of this company is seriously undervalued irrespective of the now proven ability to detect this and other virus immediately. The market appears to be in complete denial of just what this company has to offer. the share price is stupidly undervalued.

[338] 27/2/2020 14:37

I have small amount of shares bought more than 5 years ago at 12p-ish

[master rsi] 27/2/2020 14:18

World 'on brink of coronavirus pandemic': All the latest updates

Coronavirus spreading to more countries around the world, with Estonia, Denmark and Georgia confirming first cases.

The coronavirus is spreading more quickly in Europe, the Middle East and other parts of the world than in China where the virus first emerged in the central city of Wuhan at the end of last year.

The number of new infections inside China was for the first time overtaken by fresh cases elsewhere on Wednesday, with Italy, Iran and South Korea emerging as new hotspots for COVID-19.

All the latest updates

[master rsi] 27/2/2020 13:50

We Need a Cheap Way to Diagnose Coronavirus
Devabhaktuni SrikrishnaRanu S. DhillonDavid Beier - February 26, 2020

Covid-19, the new coronavirus, is on the verge of spreading across the world. Large clusters of cases are emerging outside China in South Korea, Italy, and Iran, and the Centers for Disease Control and Prevention (CDC) expects severe disruptions to occur within the United States.

More than any recent pandemic, the coronavirus poses new global challenges. As part of its recently announced $2.5 billion push for vaccines, treatments, and protective equipment, the U.S. government must also make the “crash” development of an inexpensive, point-of-care, diagnostic kit for use in clinics and homes a high priority so communities can quickly detect and contain the disease .....

[picsous] 27/2/2020 13:49

As can be seen existing tests take time and are not necessarily performed 'on site', logistics are involved which reduced accuracy.

If on the other hand BATM's offering is portable then the advantages are clear - could be a winner.

[master rsi] 27/2/2020 13:31

re- struggling

If you are struggling, get a kit for the first measure and then put a "mask" so you do not pass it on. LOL

[master rsi] 27/2/2020 13:24

Who will need kits?

Summary

Saudi Arabia is stopping foreign pilgrims entering the country
It is not clear if the Hajj pilgrimage, which begins in July this year, will be affected.

Two more patients have tested positive in the UK, bringing the total to 15
Japan plans to close all schools from 2 March.

Several European countries have announced new cases, traced to Italy

Globally, more than 80,000 people in more than 40 countries have been infected

Cases and deaths are also up in China, although mainly in Hubei

Australia extends ban on foreign visitors from mainland China

[iamgreat1] 27/2/2020 13:24

Struggling already not a good sign

[master rsi] 27/2/2020 13:15

Covid-19, the new coronavirus, is on the verge of spreading across the world.
Large clusters of cases are emerging outside China in South Korea, Italy, and Iran, and the Centers for Disease Control and Prevention (CDC) expects severe disruptions to occur within the United States. More than any recent pandemic, the coronavirus poses new global challenges. As part of its recently announced $2.5 billion push for vaccines, treatments, and protective equipment, the U.S. government must also make the “crash” development of an inexpensive, point-of-care, diagnostic kit for use in clinics and homes a high priority so communities can quickly detect and contain the disease.

For reasons we discussed earlier, vaccines can’t be developed quickly enough: They will not be available to the public for at least a year, said Francis Collins, the director of the National Institutes of Health. Complicating matters, manufacturers capable of producing the coronavirus vaccine in large quantities have yet to commit themselves to producing one being developed by the NIH, according to Tony Fauci, director of the National Institute of Allergy and Infectious Diseases.

In the meantime, the best measure is to test symptomatic patients to prevent or slow the spread of the virus. Testing can also pinpoint “hot spots” where community-wide measures like social distancing (having people avoid others, for instance, by working at home) and home isolation (requiring people with the Covid-19 to stay at home) can be considered. China is already implementing this strategy.

Testing at a broader, global scale may be necessary, however, and would require a point-of-care “rapid” diagnostic kit. We made the same case for combating the less-widespread albeit tragic Ebola and Zika crises. Such broad testing cannot depend on specialized equipment and a relative handful of centralized labs; people need to be tested in clinics and perhaps even at their doorsteps. Our most recent models indicate that in order to control coronavirus within a year, 80% of symptomatic patients would need to be tested and isolated within a day of symptoms appearing. This is consistent with our earlier published modeling for Ebola.

Currently, most pandemic-prone diseases, including coronavirus, are diagnosed by polymerase chain reaction (PCR), a molecular technique that often requires special laboratory machines and highly trained technicians to operate them. PCR tests are difficult to scale or decentralize. Bill Gates points out that portable versions of these molecular diagnostic machines need to be distributed throughout Africa to prevent the spread of coronavirus.

However running the test machines also requires a consumable test kit, and the number of coronavirus cases in China has exceeded its laboratory testing capacity due to a shortage of PCR testing kits. Consequently, China has had to resort to using CT scans as a hospital-based ..............

[master rsi] 27/2/2020 13:00

Back to square one after the RNS today

From the "UPS" thread earlier ...........

Had a 50% Intraday retracement with the UT at 48.50p and now slowly bouncing up

[andyview] 27/2/2020 12:48

I think the market reaction is relatively sanguine given the announcement and where we are with this virus globally. Added to that the array of products on offer from batm...

I've added a few more and look forward to the results next week.


gla

[kooba] 27/2/2020 12:17

I think the pathogenic waste solution is equally as interesting in current environment.Hospitals can decontaminate medical waste on site... I think this has been a big issue in China.https://youtu.be/qK1S8mmvcFI

[nellyb] 27/2/2020 12:09

deltaham, it didn't move last time he wrote. Please don't expect fireworks just yet. The day-traders will move on, trust me.

[deltaham] 27/2/2020 11:55

The IC's Simon Thompson wrote his last article on BATM on August 22 2019 entitled

"BATM’s hidden value" The share then was at 45p and he concluded with:

"Importantly, there is ample scope for positive news flow in the coming months to focus investors’ mind on BATM’s hidden balance sheet value, and the exciting commercial potential of its technology investments. A return to the April 2019 10-year share price high of 54p, and beyond looks a distinct possibility. Strong buy."

If he writes again it will move even faster.

[johndoe23] 27/2/2020 11:47

MM will lure you in, chew you up and spit you out!!

[car1pet] 27/2/2020 11:43

Wow just looked at the share price in a sea of red I thought there had been a mistake.

[prmoldoaks] 27/2/2020 11:36

Chance to get in here early guy's not done the rounds in the press yet and this company is far better regarded than Novacyt, watch their shares plummet now

Get on board this one before its press coverage latter today

[amrishbhim] 27/2/2020 11:28

This group is far bigger, and has many more products line in the market